Skip to main content

Lytenava®

GoodRx

Bevacizumab-vikg · intravitreal injection

Injections & Implants

Indication
LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Contraindications
  • Ocular or periocular infections
  • Active intraocular infections
  • Hypersensitivity
Available Forms
1.25 mg, 0.05 mL, 25 mg/mL
Mechanism of Action
Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.
Dosage
The recommended dose for LYTENAVA is 1.25 mg (0.05 mL of 25 mg/mL) administered by intravitreal injection once monthly (approximately 28 days).
Warnings & Precautions
  • Endophthalmitis and Retinal Detachments: Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering LYTENAVA.
  • Increases in Intraocular Pressure: Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately .
  • Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors.
Common Side Effects
Most common adverse reaction (≥ 4%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%).
Pregnancy & Lactation
Pregnancy: Based on the anti-VEGF mechanism of action for bevacizumab products , treatment with LYTENAVA may pose a risk to human embryofetal development. There are no adequate and well-controlled studies of LYTENAVA administration in pregnant women or pregnant animals.
Lactation: There are no data available on the presence of bevacizumab-vikg in human milk, the effects of bevacizumab-vikg on the breastfed infant or the effects of bevacizumab-vikg on milk production/excretion.
Pediatric Use
The safety and effectiveness of LYTENAVA in pediatric patients have not been established.